PMID- 27398736
OWN - NLM
STAT- MEDLINE
DCOM- 20170601
LR  - 20220408
IS  - 2168-1813 (Electronic)
IS  - 2168-1805 (Linking)
VI  - 50
IP  - 5
DP  - 2016 Oct
TI  - Reduction of quality of life in prostate cancer patients: experience among 6200 
      men in the Nordic countries.
PG  - 330-7
LID - 10.1080/21681805.2016.1201859 [doi]
AB  - OBJECTIVE: Although many studies have dealt with adverse effects (AEs) and 
      quality of life (QoL) in prostate cancer (PCa) patients, the quantification of 
      the patients' perspective on AE-related reduction in QoL has been less studied. 
      This study describes the impact of self-reported local (erectile, bowel, urinary 
      dysfunction) or systemic (mental distress, fatigue, virility loss) AEs on QoL 
      reduction. MATERIALS AND METHODS: Nordic PCa patients completed a questionnaire 
      containing 84 multiple-choice questions. The main outcome variable of the survey 
      was patient-reported PCa-induced QoL reduction, assessed by descriptive and 
      regression analyses. The level of significance was p < 0.05. RESULTS: Among 6200 
      patients, 39% described their QoL as reduced owing to the PCa trajectory: radical 
      prostatectomy group (RPGroup): 42%, radiotherapy without hormones (RADGroup): 
      27%, hormones (HormGroup): 47% and no treatment (NoTrtGroup): 19%. Except for the 
      NoTrtGroup, urinary leakage and fatigue doubled the risk of QoL reduction, while 
      virility loss and erectile dysfunction tripled the risk. Significant intergroup 
      differences emerged for the age-adjusted odds of QoL reduction: RPGroup (0.66), 
      RADGroup (0.40), HormGroup (0.95) and NoTrtGroup (0.22). CONCLUSIONS: After RP, 
      RAD or hormone treatment of PCa, systemic AEs, in particular loss of virility, 
      significantly reduce PCa patients' QoL similarly to or more than local AEs. The 
      probability of reduced QoL is highest during hormone treatment and lowest in 
      patients without anticancer therapy, and seems lower in patients treated with RAD 
      without hormones than after RP. The treatment-related risk of reduced QoL due to 
      systemic AEs should become a part of the pretreatment counselling of patients.
FAU - Fossa, Sophie D
AU  - Fossa SD
AD  - a National Advisory Unit on Late Effects after Cancer Treatment , Oslo University 
      Hospital, The Norwegian Radium Hospital , Oslo , Norway ;
FAU - Bengtsson, Thomas
AU  - Bengtsson T
AD  - b StatMind Statistical & Mathematical Modelling Innovation & Design AB , Lund , 
      Sweden ;
FAU - Borre, Michael
AU  - Borre M
AD  - c Department of Urology , Aarhus University Hospital , Aarhus , Denmark ;
FAU - Ahlgren, Goran
AU  - Ahlgren G
AD  - d Department of Urology , SUS Malmo , Region Skane, Malmo , Sweden ;
FAU - Rannikko, Antti
AU  - Rannikko A
AD  - e Department of Urology , Helsinki University Hospital , Helsinki , Finland ;
FAU - Dahl, Alv A
AU  - Dahl AA
AD  - a National Advisory Unit on Late Effects after Cancer Treatment , Oslo University 
      Hospital, The Norwegian Radium Hospital , Oslo , Norway ;
AD  - f Faculty of Medicine, University of Oslo , Oslo , Norway.
LA  - eng
PT  - Journal Article
DEP - 20160711
PL  - Sweden
TA  - Scand J Urol
JT  - Scandinavian journal of urology
JID - 101587186
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*therapy
MH  - *Quality of Life
MH  - Scandinavian and Nordic Countries
MH  - Self Report
MH  - Therapeutics/adverse effects
OTO - NOTNLM
OT  - Adverse effects
OT  - reduced quality of life
OT  - risk factors
OT  - treatment
EDAT- 2016/07/12 06:00
MHDA- 2017/06/02 06:00
CRDT- 2016/07/12 06:00
PHST- 2016/07/12 06:00 [entrez]
PHST- 2016/07/12 06:00 [pubmed]
PHST- 2017/06/02 06:00 [medline]
AID - 10.1080/21681805.2016.1201859 [doi]
PST - ppublish
SO  - Scand J Urol. 2016 Oct;50(5):330-7. doi: 10.1080/21681805.2016.1201859. Epub 2016 
      Jul 11.